Patrick Reagan, MD
Internal Medicine · Rochester, NYNPI 1467686659
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,830 of the $9,492 with a category attached, or 93.0%. Gilead accounts for 97.0% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $4,909 and has fallen 98.5% since, to $74 in 2025. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 8 payments — averaging $1186.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$9K
- Seagen Inc.$124
- Genentech USA, Inc.$74
- Astellas Pharma Global Development$59
- Acera Surgical, Inc.$25
Across 339 payments — averaging $27,743 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$6.1M
- Genentech, Inc.$1M
- Seagen Inc.$791K
- Bristol Myers Squibb$487K
- Pfizer$383K
- Astrazeneca UK Limited$161K
- plus $411K from 4 others
What the payments were for
- Consulting fees$8,83093%
- Travel & lodging$3794%
- Food & beverage$2823%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 4 | $9,209 |
| Seagen Inc. | 1 | $124 |
| Genentech USA, Inc. | 1 | $74 |
| Astellas Pharma Global Development | 1 | $59 |
| Acera Surgical, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecartus$2,500
How this compares
$9,492 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 34 | $436,439 |
| ImbruvicaIbrutinib | 18 | $303,982 |
| CalquenceAcalabrutinib Maleate | 16 | $157,476 |
| Acyclovir | 39 | $490 |
| Prochlorperazine Maleate | 23 | $279 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 39 | $114 |
| Prednisone | 43 | $86 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Rochester
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.